Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Dyadic International, Inc.

< Previous 1 2 Next >
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Expands Global Presence with Participation in Key Industry Events
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Attend Industry Events in June
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Attend Industry and Investor Events in May
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Announces Change in Board and Management Leadership Roles
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Attend Industry Events in April
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Attend Industry Events in March
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI MRVI
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Attends Investor Events in December
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Present at Industry Events in November
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic Appoints Doug Pace to Its Executive Leadership Team
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
Dyadic to Present at Industry and Investor Events in October
From Dyadic International, Inc.
Via GlobeNewswire
Tickers DYAI
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.